Beta-2-microglobulin in autism spectrum disorders

Paula Goines, Joseph Schauer, Luke Heuer, Paul Ashwood, Judith A Van de Water

Research output: Contribution to journalArticle

Abstract

Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental diseases of unknown etiology. There are no biological markers for ASD and current diagnosis is based on behavioral criteria. Recent data has shown that MHC I, a compound involved in adaptive immune function, is also involved in neurodevelopment, synaptic plasticity and behavior. It has been suggested that altered MHC I expression could play a part in neurodevelopmental diseases like ASD. To address this possibility, we measured plasma levels of beta-2-microglobulin (β2m), a molecule that associates with MHC I and is indicative of MHC I expression, in 36 children with autism, 28 typically developing controls and subjects with developmental disabilities (n=16) but not autism. The age range of our study population was 17-120 months. We found no statistically significant differences in plasma β 2m levels between groups. Therefore, plasma levels of B2m measured in early childhood in autism may not reflect changes in MHC class I in autism.

Original languageEnglish (US)
Pages (from-to)91-95
Number of pages5
JournalAmerican Journal of Biochemistry and Biotechnology
Volume3
Issue number2
StatePublished - 2007

Fingerprint

beta 2-Microglobulin
Autistic Disorder
Plasmas
Developmental Disabilities
Neuronal Plasticity
Plasticity
Molecules
Biomarkers
Autism Spectrum Disorder
Population

Keywords

  • Autism
  • Immune system
  • MHC class I

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology

Cite this

Beta-2-microglobulin in autism spectrum disorders. / Goines, Paula; Schauer, Joseph; Heuer, Luke; Ashwood, Paul; Van de Water, Judith A.

In: American Journal of Biochemistry and Biotechnology, Vol. 3, No. 2, 2007, p. 91-95.

Research output: Contribution to journalArticle

@article{01f83b56ab564ee6912c2ac37a16d7ea,
title = "Beta-2-microglobulin in autism spectrum disorders",
abstract = "Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental diseases of unknown etiology. There are no biological markers for ASD and current diagnosis is based on behavioral criteria. Recent data has shown that MHC I, a compound involved in adaptive immune function, is also involved in neurodevelopment, synaptic plasticity and behavior. It has been suggested that altered MHC I expression could play a part in neurodevelopmental diseases like ASD. To address this possibility, we measured plasma levels of beta-2-microglobulin (β2m), a molecule that associates with MHC I and is indicative of MHC I expression, in 36 children with autism, 28 typically developing controls and subjects with developmental disabilities (n=16) but not autism. The age range of our study population was 17-120 months. We found no statistically significant differences in plasma β 2m levels between groups. Therefore, plasma levels of B2m measured in early childhood in autism may not reflect changes in MHC class I in autism.",
keywords = "Autism, Immune system, MHC class I",
author = "Paula Goines and Joseph Schauer and Luke Heuer and Paul Ashwood and {Van de Water}, {Judith A}",
year = "2007",
language = "English (US)",
volume = "3",
pages = "91--95",
journal = "American Journal of Biochemistry and Biotechnology",
issn = "1553-3468",
publisher = "Science Publications",
number = "2",

}

TY - JOUR

T1 - Beta-2-microglobulin in autism spectrum disorders

AU - Goines, Paula

AU - Schauer, Joseph

AU - Heuer, Luke

AU - Ashwood, Paul

AU - Van de Water, Judith A

PY - 2007

Y1 - 2007

N2 - Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental diseases of unknown etiology. There are no biological markers for ASD and current diagnosis is based on behavioral criteria. Recent data has shown that MHC I, a compound involved in adaptive immune function, is also involved in neurodevelopment, synaptic plasticity and behavior. It has been suggested that altered MHC I expression could play a part in neurodevelopmental diseases like ASD. To address this possibility, we measured plasma levels of beta-2-microglobulin (β2m), a molecule that associates with MHC I and is indicative of MHC I expression, in 36 children with autism, 28 typically developing controls and subjects with developmental disabilities (n=16) but not autism. The age range of our study population was 17-120 months. We found no statistically significant differences in plasma β 2m levels between groups. Therefore, plasma levels of B2m measured in early childhood in autism may not reflect changes in MHC class I in autism.

AB - Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental diseases of unknown etiology. There are no biological markers for ASD and current diagnosis is based on behavioral criteria. Recent data has shown that MHC I, a compound involved in adaptive immune function, is also involved in neurodevelopment, synaptic plasticity and behavior. It has been suggested that altered MHC I expression could play a part in neurodevelopmental diseases like ASD. To address this possibility, we measured plasma levels of beta-2-microglobulin (β2m), a molecule that associates with MHC I and is indicative of MHC I expression, in 36 children with autism, 28 typically developing controls and subjects with developmental disabilities (n=16) but not autism. The age range of our study population was 17-120 months. We found no statistically significant differences in plasma β 2m levels between groups. Therefore, plasma levels of B2m measured in early childhood in autism may not reflect changes in MHC class I in autism.

KW - Autism

KW - Immune system

KW - MHC class I

UR - http://www.scopus.com/inward/record.url?scp=34147171580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147171580&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34147171580

VL - 3

SP - 91

EP - 95

JO - American Journal of Biochemistry and Biotechnology

JF - American Journal of Biochemistry and Biotechnology

SN - 1553-3468

IS - 2

ER -